{"anaplastic thyroid cancer": 1234.29, "blood alkaline phosphatase increased": 2.0, "blood creatine phosphokinase increased": 4.87, "blood lactate dehydrogenase increased": 5.98, "c-reactive protein increased": 3.81, "colitis": 2.48, "dermatitis acneiform": 17.12, "disease progression": 3.76, "drug intolerance": 2.77, "drug reaction with eosinophilia and systemic symptoms": 2.87, "drug resistance": 8.6, "ejection fraction decreased": 30.52, "erythema nodosum": 17.65, "general physical health deterioration": 2.6, "haemophagocytic lymphohistiocytosis": 15.9, "hepatic cytolysis": 2.64, "hepatitis": 2.46, "hepatotoxicity": 3.73, "hyperpyrexia": 3.24, "liver function test increased": 2.82, "lung adenocarcinoma": 27.7, "maligt melanoma": 77.04, "maligt melanoma stage iv": 191.43, "maligt neoplasm progression": 32.4, "melanoma recurrent": 146.38, "metastases to bone": 9.09, "metastases to central nervous system": 77.81, "metastases to liver": 12.99, "metastases to lung": 26.84, "metastases to lymph nodes": 27.11, "metastases to meninges": 49.71, "metastases to skin": 85.07, "metastasis": 15.0, "metastatic maligt melanoma": 484.61, "mucosal inflammation": 4.13, "neoplasm progression": 2.22, "neutropenia": 3.39, "non-small cell lung cancer": 13.33, "panniculitis": 60.18, "peripheral motor neuropathy": 58.25, "peripheral sensory neuropathy": 13.32, "pneumonitis": 6.85, "polyneuropathy": 4.8, "product use in unapproved indication": 7.0, "pulmonary mass": 7.05, "pyrexia": 2.37, "rhabdomyolysis": 3.16, "skin toxicity": 27.21, "therapeutic response decreased": 7.7, "therapy partial responder": 48.3, "uveitis": 37.35}